부산대학교 도서관

We investigated peripheral blood progenitor cell (PBPC) mobilization by disease-specific chemotherapy in patients with metastatic soft tissue sarcoma (STS). Nine patients, five females and four males, aged 12-51 years, pretreated by one to nine courses of cytotoxic chemotherapy, underwent STS-specific mobilization followed by G-CSF at 5 μg/kg/day. PBPC were collected by 19 conventional-volume aphereses (8-12 1) with one to four procedures in individual patients. Leukaphereses started on median day 15 (range 13-18) from the first day of mobilization chemotherapy at medians of 25.8 x 10³ WBC/μl (6.8-46.9), 3.5 x 10³ MNC/μl (1.18.8), 122 x 10³ platelets/μl (72-293) and 30.7 CD34+ cells/μl (6.7-207.8). Cumulative harvests resulted in medians of 4.6 x l0[sup8] MNC/kg (3.0-6.4), 2.9 x 10[sup6] CD34+ cells/kg (1.1-11.1) and 12.0 x 10[sup4] CFU-GM/kg (2.0-37.8). Eight patients underwent high-dose chemotherapy (HDCT) followed by PBPC rescue. Seven patients recovered hematopoiesis at medians of 12 days (8-15) for ANC >0.5 x 10³/μl and 14 days (8-27) for platelets >20 x 10³/μl. One patient, who received 1.6 x 10[sup6] CD34+ cells/kg, exhibited delayed ANC recovery on day +37 and failed to recover platelets until hospital discharge on day +55. We conclude that in patients with metastatic STS, who are pretreated by standard chemotherapy, PBPC can be mobilized by a further course of STS-specific chemotherapy plus G-CSF. One to four conventional-volume aphereses result in PBPC autografts that can serve as hematopoietic rescue for patients scheduled for HDCT. [ABSTRACT FROM AUTHOR]